S&T Bank’s Royalty Pharma RPRX Stock Holding History

S&T Bank’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8	Closed	-$309	–	427
2025 Q4	$309	Hold	8	–	–	﹤0.01%	405
2025 Q3	$282	Buy	+8	New	+$290	﹤0.01%	471

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

S&T Bank's RPRX Position: Q1 2026 in Review

S&T Bank sold out of Royalty Pharma (RPRX) in Q1 2026, closing a stake of 8 shares — an estimated $309 sold.

S&T Bank first reported a position in RPRX in Q3 2025 and held it in 2 quarters. The position peaked at $309 in Q4 2025. 590 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

S&T Bank reported no remaining Royalty Pharma position as of Q1 2026 after selling out during the quarter.
S&T Bank sold 8 Royalty Pharma shares in Q1 2026, an estimated $309.
S&T Bank first reported a position in Royalty Pharma in Q3 2025 and held it in 2 quarters.
S&T Bank's Royalty Pharma position peaked at $309 in Q4 2025.
590 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on S&T Bank's 13F filing for Q1 2026, filed 13 May 2026.